REFERENCES
- Arai Y., Nonomura N., Nakai Y., Nishimura K., Oka D., Shiba M., Nakayama M., Takayama H., Mizutani Y., Miki T., Okuyama A. The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro. Cancer Invest 2008; 26(1)35–40
- Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I. G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R. J. Global ARCC trial. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 2007; 356(22)2271–2281
- Christophersen A. O., Lie A. K., Fossa S. A. Unexpected 10 years complete remission after cortisone mono-therapy in metastatic renal cell carcinoma. Acta Oncol 2006; 45(2)226–228
- Iwai A., Fuji Y., Kawakami S., Takazawa R., Kageyama Y., Yoshida M. A., Kihara K. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids. Mol Cell Endocrinol 2004; 226(1–2)11–17
- Takenawa J., Kaneko Y., Okumura K., Yoshida O., Nakayama H., Fujita J. Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinomas and effects on expression on interleukin-6 or interleuking-6 receptor. J Urol 1995; 153(3 Pt 1)858–862
- Tanaka M., Fukuda H., Higashi Y. A case of complete regression of metastatic renal cell carcinoma following corticosteroid treatment. Hinyokika Kiyo 2003; 49(4)225–228